Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?
Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell, Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP) and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and increases accessibility of tumor cells to anticancer drugs.